louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01915004: The Effectiveness of a Bladder Training Video for Management of Lower Urinary Tract Symptoms.
Official title: Bladder Training Video Versus Individual Urotherapy for Children With Non-neurogenic Lower Urinary Tract Dysfunction.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nonneurogenic Lower Urinary Tract Dysfunction
Dysfunctional Elimination Syndrome
Keywords: Pediatric Urology
Urotherapy
Nonneurogenic Lower Urinary Tract Dysfunction
Dysfunctional Elimination Syndrome
Randomized Controlled Trial
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: Canadian Urological Association
First posted: 2013-08-02
Enrollment: 150
Sex: ALL
Minimum age (years): 5
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Children with non-neurogenic lower urinary tract dysfunction (NLUTD) represent a significant subgroup of pediatric urology patients, comprising up to 30 percent of some out-patient clinics. These children present with urinary tract infections (UTIs), abnormal voiding habits and various other lower urinary tract symptoms (LUTs) such as incontinence, urinary urgency and urinary frequency. Furthermore, the effects of NLUTD on a child's physical health, mental health and its potential negative clinical sequelae, which includes upper or lower urinary tract damage, must be taken into account when treating these children. These patients have complex needs requiring a significant amount of health teaching and it is imperative to determine the effectiveness of the various modes of delivering urotherapy. To determine the best modality to deliver urotherapy, this trial will compare the effectiveness of a 7 minute bladder training video to the effectiveness of standard urotherapy provided at a pediatric urology clinic at improving NLUTD/DES symptoms and quality of life in children between 5-10 years of age.


Eligibility criteria: Inclusion Criteria:

* Children aged 6-10 years old
* Bladder Dysfunction (Diagnosis of NLUTD or DES)

Exclusion Criteria:

* Grade 3 or 4 hydronephrosis
* Grade 3, 4 or 5 vesicoureteral reflux
* Other diagnoses which affect bladder bowel function (i.e. Spina Bifida)
* English as a second language
* Diagnosed learning disability (i.e. ADD or ADHD)
* Mental health condition (i.e. anxiety or depression)
* Received intensive urotherapy and biofeedback in past 12 months
* Child is diagnosed with primary nocturnal enuresis

Primary outcomes:
measure: Improvement of Nonneurogenic Lower Urinary Tract Dysfunction symptoms
timeFrame: up to 12 weeks
Secondary outcomes:
measure: Assess the Quality of Life of children with Nonneurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome.
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: McMaster University Medical Centre
state: Ontario
Study officials:
affiliation: McMaster University
name: Luis Braga, MD, FRCSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01617304: Effects of Food Cooking on Diabetes-2 Risk Factors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Type 2 Diabetes
Insulin Resistance
Cardiovascular Disease
Keywords: advanced glycation end products
insulin sensitivity
obesity
inflammation
metabolomics
appetite
CVD
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: The Ministry of Science, Technology and Innovation, Denmark
First posted: 2012-06-12
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the project is to investigate the effects of advanced glycation end products (AGEs) formed in food during the cooking process as well as AGEs formed naturally in the human body, on insulin sensitivity and risk factors for type 2 diabetes. The hypothesis is that i) food content of AGEs is lower using boiling and steaming cooking methods and that ii) AGEs formation in the body is lower at low dietary intake of certain sugar forms.


Eligibility criteria: Inclusion Criteria:

* women, healthy between 20 and 50 y
* BMI between 25 and 40 kg/m2
* weight circumference over 88 cm

Exclusion Criteria:

* weigh changes within the last 2 months more than +/- 3 kg
* Physical activity more than 8 h per week
* smoking
* medications and supplements
* being vegetarian or vegan
* pregnancy or breast feeding
* postmenopause
* chronic disease
* previous gastric bypass surgery
* blood donation within the last 3 months
* Involvement in other clinical trials
* allergic to paraaminobenzoic acid

Primary outcomes:
measure: change in HOMA from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in OGTT from baseline to 4 weeks
timeFrame: 0 and 4 weeks at 0 and 120 min
measure: change in appetite hormones (leptin, adiponectin, GLP-1, glukagon, ghrelin) from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in plasma and urin AGEs from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in immune response (CRP, C-peptide, IL-1B, IL-6, VCAM, ICAM, MIF, TNF-a, buffycoat) from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in metabolomics dats from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in AGE levels in skin from baseline to 4 weeks
timeFrame: 0 and 4 weeks
Secondary outcomes:
measure: change in lipid profile (TG, Chol, LDL, HDL, ox LDL, glycated LDL, fattyacids)from baseline to 4 weeks
timeFrame: 0 and 4 weeks
measure: change in HbA1c from baseline to 4 weeks
timeFrame: 0 and 4 weeks
Other outcomes:
Locations:
city: Frederiksberg
country: Denmark
facility: Department of Human Nutrition, University of Copenhagen
Study officials:
affiliation: Department of Human Nutrition, University of Copenhagen
name: Susanne G Bugel
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01670604: Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures
Official title: The Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures: Effect on Acid-Base Status and Renal Functions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Urologic Surgical Procedures
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2012-08-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study compares the effect of infusion of two types of modern hydroxyethyl starch on the renal function and acid-base in patients undergoing urologic surgery.


Eligibility criteria: Inclusion Criteria:

* Age group above 18 years,
* ASA І and ІІ,
* Patients who will be scheduled to undergo radical prostatectomy or cystectomy with bladder replacement

Exclusion Criteria:

* A known allergy to HES,
* Renal insufﬁciency (serum creatinine of \>2.5 mg/dL),
* Signiﬁcant hepatic disease (liver function tests more than three times the upper limit of normal),
* Coagulation disorders (INR \> 1.5).

Primary outcomes:
measure: Intraoperative volume replacement therapy
timeFrame: From randomization, for the duration of surgery and up to transfer from the operating room to the ICU or recovery room, an expected average of 6 hours
Secondary outcomes:
measure: Acid base and Renal function
timeFrame: 24 hours after randomization
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasralainy Hospital
Study officials:
References:
citation: Kluft C, Jenks RL, Astrup T. Production of plasminogen actovatpr activity in factor XII-deficient plasma. Thromb Res. 1977 May;10(5):759-64. doi: 10.1016/0049-3848(77)90058-5. No abstract available.
citation: Takayanagi I, Maruyama M, Takagi K. Beta-adrenoceptors in the guinea pig treated with egg-albumin. Jpn J Pharmacol. 1977 Apr;27(2):314-6. doi: 10.1254/jjp.27.314. No abstract available.
citation: Mitchell AR, Erickson BW, Ryabtsev MN, Hodges RS, Merrifield RB. Tert-butoxycarbonylaminoacyl-4-(oxymethyl)-phenylacetamidomethyl-resin, a more acid-resistant support for solid-phase peptide synthesis. J Am Chem Soc. 1976 Nov 10;98(23):7357-62. doi: 10.1021/ja00439a041. No abstract available.
citation: Birke ER. [On the action of antihypotensive agents in sympathicotonic orthostatic hypotension in geriartric patients: comparison between placebo and etilefrin (author's transl)]. Med Klin. 1977 Oct 14;72(41):1696-702. German.
Clinical trial NCT04487704: Camrelizumab Utilization on Patients With Advanced Liver Cancer
Official title: A Real World Study of Treatment Regimens Containing Camrelizumab in Patients With Advanced Liver Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Advanced Hepatocellular Carcinoma
Keywords: RWS
Advanced Liver Cancer
PD-1
Lead sponsor: First Affiliated Hospital Xi'an Jiaotong University
Sponsor class: OTHER
First posted: 2020-07-27
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer

Detailed description: camrelizumab ， a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high affinity for PD-1 (KD = 3.31 nmol/L), a high acceptor proportion (85% at 200 mg) of circulating T lymphocytes, and binds to epitopes different from Nivolumab and pembrolizumab，Phase 1 clinical trials have shown that camrelizumab is well tolerated and has antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for indication for advanced hepatocellular carcinoma The main objective of this study was to observe and evaluate the safety and efficacy of treatment regiments containing Camrelizumab in advanced liver cancer。 The subjects included people over 18 years old， For men and women with advanced liver cancer confirmed by histopathology or cytology;

Eligibility criteria: Inclusion Criteria:

* 18 years old or more;
* For both men and women;
* Patients with advanced liver cancer confirmed by histopathology or cytology; .Volunteer to join the study, sign the informed consent, good compliance, and cooperate with the follow-up.

Exclusion Criteria:

* A known allergy to the study drug or any of its excipients; Or had a severe allergic reaction to other monoclonal antibodies;
* Patients who are ready for or have previously received an organ or allogeneic bone marrow transplant;
* Pregnant or lactating women;
* According to the judgment of the researcher, the patients should not be included in this study

Primary outcomes:
measure: Assess Safety as defined by the NCI CTCAE v5.0
timeFrame: From patients participate in the clinical study to 90 days after the end of treatment
Secondary outcomes:
measure: overall survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Xi'an
country: China
facility: First Affiliated Hospital of Xi'an Jiaotong University
state: Shanxi
Study officials:
affiliation: First Affiliated Hospital Xi'an Jiaotong University
name: Yi Lyu, MD,phD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04672304: Long Term and Permanent Contraceptive
Official title: Factors Affecting the Use of Long Term and Permanent Contraceptive Methods; Cross Sectional Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraceptive Behavior
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 1365
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 49
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women aged 15-49 years of age

Brief summary: We will study with the different variables that affect the intention to use long- acting and permanent contraceptive methods among married women in Jordan through a cross sectional study. Self- administered questionnaire will be distributed to aid in data collection.

Detailed description: In this cross-sectional study, self-administered pre-made questionnaires. (https://docs.google.com/forms/d/e/1FAIpQLSdjuuQynIxu0AAmIbKHg0-iyZgTW0m5847JaX0OZrnl7v7v1w/viewform ) will be distributed to married women. (Women of childbearing age). The candidates will be selected according to their age (15-49), marital status (married), and pregnancy status (non-pregnant). The data collected through the questionnaires will then be processed and interpreted in order to understand the variables that affect the use of LACM and permanent contraception methods among Jordanian women.

Eligibility criteria: Inclusion Criteria:

* females used or currently using long-term contraception

Exclusion Criteria:

* never users of contraception

Primary outcomes:
measure: The use of LACM and permanent contraception methods measure by a questionnaire
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Jordan University Hospital
Study officials:
References:
Clinical trial NCT00535704: Preventing Substance Use and Risky Behavior Among Rural African American Youth
Official title: Preventing Substance Use and Risky Behavior Among Rural African American Youth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Risky Sexual Behavior
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2007-09-26
Enrollment: 502
Sex: ALL
Minimum age (years): 14
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The Rural African American Families Health (RAAFH) Project is a federally funded research study designed to evaluate the effectiveness two prevention programs designed for rural African American families. One program, FUEL, helps teens develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress. The second program, the Strong African American Families Teen Program (SAAF-T), helps teens learn how to develop plans for the future and to avoid drug use and unsafe sex. The sessions deal with goal setting, peer pressure, and staying in school.


Eligibility criteria: Inclusion Criteria:

* African American student in 10th grade
* Agree to randomization and assessment
* Resides in targeted county
* Target and parent speak English

Exclusion Criteria:

* Active psychoses

Primary outcomes:
measure: Sexual behavior
timeFrame: 3 months
Secondary outcomes:
measure: Substance Use
timeFrame: 3 months
Other outcomes:
Locations:
city: Athens
country: United States
facility: Center for Family Research
state: Georgia
Study officials:
affiliation: University of Georgia
name: Gene H Brody
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04399304: Safety of Bilateral HTO: One-Stage vs.Two-Stage: A Randomized Controlled Study
Official title: Safety of Bilateral HTO: One-Stage vs.Two-Stage: A Randomized Controlled Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gonarthrosis; Primary
Varus Gonarthrosis
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2020-05-22
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with bilateral genu varus gonarthrosis operated by the tertiary step hospital high-volume knee surgeons

Brief summary: In this study, bilateral simultaneous high tibial osteotomy (HTO) was compared with staged bilateral HTO in terms of complications. We did not use any grafts to support the osteotomy line and the patients were mobilized immediately with a full load on a postoperative day 1. And our hypothesis is that bilateral simultaneous applications are safe in comparison to the staged ones in terms of complications.

Detailed description: Knee osteoarthritis is the most common orthopedic chronic disease, and varus knee abnormalities can often be related. The load from the medial tibiofemoral joint increases significantly in varus alignment disorder and it plays an important role in the structural progression of knee osteoarthritis. Varus malalignment and patients with medial tibiofemoral disease comprise a common patient subset. The probability of progressing to severe disease is 3 to 4 times higher in these patients compared to those with a neutral knee alignment. Although the long-term results of high tibial osteotomy are well documented, but data on bilateral simultaneous HTO are insufficient. In general, staged surgery is preferred in bilateral cases due to the difficult rehabilitation, healing of the osteotomy line, and complications related to surgery. Advances in post-surgical rehabilitation have been made due to increased confidence in stability due to improvements in the technology of plates.The advantages of an bilateral simulatneous HTO is single administration of anesthesia, total shortening of the hospitalization periof and reduced costs.

Eligibility criteria: Inclusion Criteria:

* Bilateral primary genu varus gonarthrosis

Exclusion Criteria:

* Secondary gonarthrosis

Primary outcomes:
measure: Complications
timeFrame: 2 year
Secondary outcomes:
measure: Radiologic assesment
timeFrame: 2 year
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
state: Fatih
Study officials:
References:
Clinical trial NCT00300404: Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
Official title: Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Major Depression
Keywords: Schizophrenia
Psychosis
Depression
Affective Disorder
Lead sponsor: Zentrum für Integrative Psychiatrie
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2006-03-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.


Eligibility criteria: Inclusion Criteria:

* Schizophrenia or Major Depression
* Both genders
* Adult
* Patients are able to give informed consent

Exclusion Criteria:

* Additional diagnosis of substance abuse/dependency
* Continuous treatment with medication not compatible with study medication
* Medical status not compatible with study medication
* Any condition that increases study risk considerably
* Pregnancy, nursing

Primary outcomes:
measure: Psychopathology ratings
Secondary outcomes:
measure: TG infection parameters
Other outcomes:
Locations:
Study officials:
affiliation: Zentrum für Integrative Psychiatrie
name: Dunja Hinze-Selch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06322004: Video-Interpreting in Prehospital Emergency Medicine - Feasibility Study
Official title: Video-Interpreting in Prehospital Emergency Medicine - Feasibility Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Communication Barriers
Keywords: Communication barriers
Prehospital emergency medicine
Emergency medicine
Emergency physician
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2024-03-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 50 responsive patients treated by prehospital emergency doctors of the Department of Anaesthesia, Intensive Care and Pain Management (Medical University of Vienna/ General Hospital of Vienna) with language barrier (14 languages Albanian, Dari, Romanian, Turkish, Modern Standard Arabic, Arabic, Farsi, Russian, Hungarian, Bosnian-Croatian-Serbian, Kurdish (Kurmanci), Slovakian, Bulgarian, Polish, and Czech) will be included regarding inclusion and exclusion criteria mentioned above.

Brief summary: 50 responsive patients with language barriers will be included in this study. The prehospital emergency physician will start video-interpreting via a tablet. Feasibility, quality of communication, usability as well as changes in diagnosis and treatment will be gathered and analysed.


Eligibility criteria: Inclusion Criteria:

* adult patients, at least 18 years old
* awake, responsive patients
* language barrier (Albanian, Dari, Romanian, Turkish, Modern Standard Arabic, Arabic, Farsi, Russian, Hungarian, Bosnian-Croatian-Serbian, Kurdish (Kurmanci), Slovakian, Bulgarian, Polish, and Czech)

Exclusion Criteria:

* unconscious patients
* out-of-hospital cardiac arrest patients
* delay of treatment or transportation due to e-interpreting
* refusal of video-interpreting by the patient

Primary outcomes:
measure: Technical Feasibility
timeFrame: Immediately after use of video-interpreting
measure: Usability of video-interpreting
timeFrame: Immediately after use of video-interpreting
measure: Impact on emergency physician's decisions
timeFrame: Immediately after use of video-interpreting
Secondary outcomes:
measure: Demographic parameters
timeFrame: Immediately after use of video-interpreting
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
References:
Clinical trial NCT01484704: The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mammary Ductal Carcinoma
Keywords: Carcinoma ductale mammae
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2011-12-02
Enrollment: 100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Newly diagnosted breast cancer patients

Brief summary: The purpose of this study is to determine how MRI changes the treatment and diagnostics of ductal breast cancer. 100 women with newly diagnosed breast cancer will participate the study.


Eligibility criteria: Inclusion Criteria:

* Tumor size less than 2cm
* Ductal carcinoma unifocal

Exclusion Criteria:

* Previous breast cancer

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: University hospital of Turku
Study officials:
References: